Superpower peptides available for pre-order. Get first access.

Peptide science

What is SLU-PP-332?

SLU-PP-332 is a synthetic pan-ERR agonist, not a peptide. See what mouse studies found, why no human data exists, and its FDA and anti-doping status.

Quick answer

SLU-PP-332 is a synthetic small molecule, not a peptide, that activates all three estrogen-related receptors. In mice it increased treadmill endurance, and a 2024 study found less fat gain in obese models. No human study exists, no trial is registered as of November 2026, and the compound has no FDA approval. Gray-market products carry unknown purity and risk.

Published
April 18, 2026
Last updated
November 12, 2026

Key takeaways

What is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule, not a peptide, developed at Saint Louis University as a pan-agonist of the receptors ERRα, ERRβ, and ERRγ4. The "SLU-PP-332 peptide" label turns up across sellers and search results, and it is a misclassification.

Estrogen-related receptors are their own family, close in structure to estrogen receptors but unable to bind the body's own estrogens3. The compound has no trade name and no peptide-style synonym. What draws attention to SLU-PP-332 is the receptor family it switches on.

How SLU-PP-332 works

SLU-PP-332 activates all three estrogen-related receptors, transcription factors that switch on genes for mitochondrial biogenesis and fuel oxidation3. Aerobic exercise recruits much of the same gene program.

These receptors stay active without a hormone binding them, and no natural ligand has been found6.

Genetics show what the pathway is worth to a muscle. A bout of exercise raises ERR levels in human skeletal muscle7. Mice missing ERRα and ERRγ in muscle show decreased oxidative capacity and severe exercise intolerance7. Mice engineered for constant ERRα activity ran longer before fatiguing8.

ERRs share this work with PGC-1α and other regulators of mitochondrial biogenesis9, so no single agonist reproduces training in full. That limit frames what the animal studies measured.

What preclinical research has found

In mice, SLU-PP-332 increased treadmill endurance4, slowed fat gain and improved insulin sensitivity5 in obese models, and improved heart function after pressure overload10. No human study of any kind has been published.

Research focusModelWhat researchers saw
Exercise capacityMice and a skeletal muscle cell lineMore oxidative fibers and greater treadmill endurance4
Metabolic syndromeDiet-induced obese and ob/ob miceHigher energy expenditure, less fat mass, better insulin sensitivity5
Heart failureMice after pressure overloadHigher ejection fraction, less fibrosis, longer survival10
Aging kidneyMice aged 21 months, dosed for 8 weeksLower albuminuria, less podocyte loss, and better mitochondrial function11
Oral successor SLU-PP-915MiceRunning gains held up12 when the compound was given by mouth

One pharmacokinetic fact keeps SLU-PP-332 in the laboratory. It improves aerobic performance in mice but lacks oral bioavailability12, so the animal work injected it. A medicinal chemistry series answered that with SLU-PP-915, a more metabolically stable pan-ERR agonist13. Even the successor is a mouse compound, a long way from the claim that made SLU-PP-332 famous.

Exercise in a pill is an unproven idea

SLU-PP-332 is not a substitute for exercise. Candidate exercise pills have targeted skeletal muscle14 and missed what training does elsewhere. Training shifts mitochondrial health, vascular function, autonomic balance, and inflammation15 at once.

Compounds in this class are defined as agents that switch on exercise-like signaling16, and nearly everything known about them comes from rodents. AICAR and MOTS-c chased the same goal through a different enzyme. Adults are still advised to get 150 to 300 minutes of moderate activity17 a week.

SLU-PP-332 also pulls a different lever than the incretin drugs. Mice given SLU-PP-332 spent more energy and oxidized more fat5. Semaglutide and tirzepatide instead reduced appetite and energy intake18 in adults with type 2 diabetes. SLU-PP-332 itself carries no approval of any kind.

Regulatory status and anti-doping classification

SLU-PP-332 has no FDA approval, no Investigational New Drug application, and no registered trials of any phase1 as of November 2026. It remains a research tool compound, a chemical probe for studying ERR activation19.

In sport, the current Prohibited List does not name SLU-PP-33220. Its opening class covers any substance lacking approval for human therapeutic use20, preclinical drugs included. Anti-doping laboratories have already built the groundwork for a test, identifying 22 metabolites in human liver preparations21 and characterizing both compounds by mass spectrometry22.

What sells online under this name sits outside regulated supply. Among 44 products marketed online as selective androgen receptor modulators, only 52% contained any compound from the advertised class23. Nobody buying that way knows what is in the vial.

Who should not use SLU-PP-332

Nobody outside an approved research study has an evidence-based reason to take SLU-PP-332. No human has received it under controlled conditions, so there is no established dose and no safety profile.

Activating these receptors also reaches well past muscle. ERRα overexpression drives breast cancer progression24 in preclinical work, which leaves broad receptor activation an open question in people. Athletes carry the added risk that detection methods are in development.

Where can I learn about peptides?

SLU-PP-332 is a small molecule that search engines and sellers keep filing with peptides. A team of health journalists and licensed clinicians writes and fact-checks Superpower’s peptide library, compound by compound.

Mitochondrial biogenesis, receptor agonism, and oral bioavailability come up across this field. The science behind peptides explains how these molecules are built, what they target, and how far their evidence reaches.

Important safety information

SLU-PP-332 is not approved by the FDA for any medical use. Research on this compound has been limited primarily to laboratory and animal studies, with little to no human clinical trial data available. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. SLU-PP-332 is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

No human safety data exists for SLU-PP-332. All pharmacological and efficacy data are derived from mouse studies. The compound cannot be presumed safe or tolerable in humans based on animal findings. Adverse effects in humans are unknown.

SLU-PP-332 has poor oral bioavailability. Its pharmacokinetics in humans have not been studied. Gray-market material sold as SLU-PP-332 is uncontrolled in purity, identity, and dosage. Purchase or use of such material carries unknown risks and no legitimate therapeutic basis.

ERR agonism affects cardiac metabolism in preclinical models. The cardiac safety profile of SLU-PP-332 in humans has not been evaluated. Any human exposure to this compound would occur without established cardiovascular safety data.

Anti-doping: As of November 2026, the World Anti-Doping Agency Prohibited List does not name SLU-PP-332, but its S0 class prohibits at all times any substance without current approval for human therapeutic use. In vitro metabolism studies published in 2026 support the development of detection methods. Athletes subject to anti-doping regulations should regard this compound as carrying detection risk.

SLU-PP-332 should not be used by anyone outside an IRB-approved clinical research study; there is no approved indication and no contraindication table because there is no approved use. Always consult a qualified healthcare provider before making changes to your health routine.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to SLU-PP-332. SLU-PP-332 is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science